Literature DB >> 18845793

Pronounced thrombocytosis in transgenic mice expressing reduced levels of Mpl in platelets and terminally differentiated megakaryocytes.

Ralph Tiedt1, Jörn Coers, Sandra Ziegler, Adrian Wiestner, Hui Hao-Shen, Caroline Bornmann, Johannes Schenkel, Svetlana Karakhanova, Frederic J de Sauvage, Carl W Jackson, Radek C Skoda.   

Abstract

We generated mice expressing a full-length Mpl transgene under the control of a 2-kb Mpl promoter in an Mpl(-/-) background, effectively obtaining mice that express full-length Mpl in the absence of other Mpl isoforms. These mice developed thrombocytosis with platelet levels approximately 5-fold higher than wild-type controls and markedly increased megakaryocyte numbers. The reintroduction of one wild-type Mpl allele restored normal platelet counts. We excluded the deletion of Mpl-tr, a dominant-negative isoform, as the underlying molecular cause for thrombocytosis. Instead, we found that transgene expression driven by the 2-kb Mpl promoter fragment was decreased during late megakaryocyte maturation, resulting in strongly diminished Mpl protein expression in platelets. Because platelets exert a negative feedback on thrombopoiesis by binding and consuming Tpo in the circulation through Mpl, we propose that the severe reduction of Mpl protein in platelets in Mpl-transgenic Mpl(-/-) mice shifts the equilibrium of this feedback loop, resulting in markedly elevated levels of megakaryocytes and platelets at steady state. Although the mechanism causing decreased expression of Mpl protein in platelets from patients with myeloproliferative disorders differs from this transgenic model, our results suggest that lowering Mpl protein in platelets could contribute to raising the platelet count.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18845793     DOI: 10.1182/blood-2008-03-146084

Source DB:  PubMed          Journal:  Blood        ISSN: 0006-4971            Impact factor:   22.113


  28 in total

1.  Imputation of exome sequence variants into population- based samples and blood-cell-trait-associated loci in African Americans: NHLBI GO Exome Sequencing Project.

Authors:  Paul L Auer; Jill M Johnsen; Andrew D Johnson; Benjamin A Logsdon; Leslie A Lange; Michael A Nalls; Guosheng Zhang; Nora Franceschini; Keolu Fox; Ethan M Lange; Stephen S Rich; Christopher J O'Donnell; Rebecca D Jackson; Robert B Wallace; Zhao Chen; Timothy A Graubert; James G Wilson; Hua Tang; Guillaume Lettre; Alex P Reiner; Santhi K Ganesh; Yun Li
Journal:  Am J Hum Genet       Date:  2012-10-25       Impact factor: 11.025

2.  Mpl expression on megakaryocytes and platelets is dispensable for thrombopoiesis but essential to prevent myeloproliferation.

Authors:  Ashley P Ng; Maria Kauppi; Donald Metcalf; Craig D Hyland; Emma C Josefsson; Marion Lebois; Jian-Guo Zhang; Tracey M Baldwin; Ladina Di Rago; Douglas J Hilton; Warren S Alexander
Journal:  Proc Natl Acad Sci U S A       Date:  2014-04-07       Impact factor: 11.205

3.  JAK2 and MPL protein levels determine TPO-induced megakaryocyte proliferation vs differentiation.

Authors:  Rodolphe Besancenot; Damien Roos-Weil; Carole Tonetti; Hadjer Abdelouahab; Catherine Lacout; Florence Pasquier; Christophe Willekens; Philippe Rameau; Yann Lecluse; Jean-Baptiste Micol; Stefan N Constantinescu; William Vainchenker; Eric Solary; Stéphane Giraudier
Journal:  Blood       Date:  2014-08-20       Impact factor: 22.113

Review 4.  Mouse models of diseases of megakaryocyte and platelet homeostasis.

Authors:  Catherine L Carmichael; Warren S Alexander
Journal:  Mamm Genome       Date:  2011-06-11       Impact factor: 2.957

5.  Genetic studies reveal an unexpected negative regulatory role for Jak2 in thrombopoiesis.

Authors:  Sara C Meyer; Matthew D Keller; Brittany A Woods; Lindsay M LaFave; Lennart Bastian; Maria Kleppe; Neha Bhagwat; Sachie Marubayashi; Ross L Levine
Journal:  Blood       Date:  2014-08-12       Impact factor: 22.113

6.  The thrombopoietin receptor, MPL, is critical for development of a JAK2V617F-induced myeloproliferative neoplasm.

Authors:  Veena Sangkhae; S Leah Etheridge; Kenneth Kaushansky; Ian S Hitchcock
Journal:  Blood       Date:  2014-10-22       Impact factor: 22.113

7.  Role of tumor suppressor p53 in megakaryopoiesis and platelet function.

Authors:  Pani A Apostolidis; Donna S Woulfe; Massiel Chavez; William M Miller; Eleftherios T Papoutsakis
Journal:  Exp Hematol       Date:  2011-10-21       Impact factor: 3.084

8.  Mpl traffics to the cell surface through conventional and unconventional routes.

Authors:  Cédric Cleyrat; Anza Darehshouri; Mara P Steinkamp; Mathias Vilaine; Daniela Boassa; Mark H Ellisman; Sylvie Hermouet; Bridget S Wilson
Journal:  Traffic       Date:  2014-07-18       Impact factor: 6.215

9.  Gene therapy of MPL deficiency: challenging balance between leukemia and pancytopenia.

Authors:  Daniel C Wicke; Johann Meyer; Guntram Buesche; Dirk Heckl; Hans Kreipe; Zhixiong Li; Karl H Welte; Matthias Ballmaier; Christopher Baum; Ute Modlich
Journal:  Mol Ther       Date:  2009-10-20       Impact factor: 11.454

10.  Incomplete restoration of Mpl expression in the mpl-/- mouse produces partial correction of the stem cell-repopulating defect and paradoxical thrombocytosis.

Authors:  Brian J Lannutti; Angela Epp; Jacqueline Roy; Junmei Chen; Neil C Josephson
Journal:  Blood       Date:  2008-09-16       Impact factor: 22.113

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.